Prevnar by Pfizer

SCROLL FOR IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

• Prevnar 20™ should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 20 or to diphtheria toxoid
• Adults with weakened immune systems may have a lower response to Prevnar 20. Safety data are not available for these groups. Your healthcare provider can tell you if Prevnar 20 is right for you
• In adults 18 years of age and older, the most common side effects were pain at the injection site, muscle pain, fatigue, headache, and joint pain. Additionally, injection site swelling was also common in adults 18 through 59 years of age
• Ask your healthcare provider about the risks and benefits of Prevnar 20. Only a healthcare provider can decide if Prevnar 20 is right for you

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

INDICATION FOR PREVNAR 20

• Prevnar 20 is a vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
• The indication for preventing pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved based on immune responses. Continued approval may depend on a supportive study

Please see full Prescribing Information

(https://bit.ly/3cxNq7o)

Manufactured by Wyeth Pharmaceuticals LLC.

Marketed by Pfizer Inc.

PP-PNR-USA-0373-30 May 2022

Please see full Prescribing Information here.